Novo seen to benefit from Pfizer-Biocon split

Tools

Pfizer ($PFE) and Biocon's decision to dissolve their partnership was bad news for the Indian company's stock, as analysts downgraded their sales estimates for its insulin products. But Novo Nordisk ($NVO), the Danish diabetes specialist, got a boost. Report

Filed Under